e-Posters List

Abstract Number	Title	Presenting Author
ABS001	ACQUIRED FACTOR VIII INHIBITOR IN A PATIENT WITH STILL’S DISEASE	Imen Krichen
ABS002	ANALYSIS OF HEMOPHILIA PATIENT IDENTIFICATION IN DIFFERENT ECONOMIC SETTINGS	Ellia Tootoonchian
ABS003	CONCOMITANT USE OF ADVATE® AND EMICIZUMAB IN PATIENTS WITH HAEMOPHILIA A: RESULTS AND ANALYSIS FROM A UK NEQAS BC EMICIZIMAB EXERCISE.	Anna Lowe
ABS004	ENHANCEMENT OF COAGULATION BY EMICIZUMAB VIA INTRINSIC PATHWAY AS DETECTED WITH THROMBOELASTOMETRY	Timea Szanto
ABS005	EQUITY IN THE USE OF PROPHYLAXIS IN CHILDREN WITH SEVERE HEMOPHILIA	Ellia Tootoonchian
ABS006	EVALUATION OF THE BIOPHEN FVIII:C BOVINE R1 KIT FOR THE MEASUREMENT OF FACTOR VIII INHIBITORS IN HEMOPHILIA A PATIENTS TREATED WITH EMICIZUMAB.	Louise Guillaume
ABS007	EVALUATION OF TWO DIFFERENT CHRONOMETRIC DOSAGES FOR EMICIZUMAB CONCENTRATION MEASUREMENT IN SEVERE HEMOPHILIA A PATIENTS	Amélie Launois
ABS009	FC-GAMMA RECEPTOR POLYMORPHISMS AND THE OUTCOME OF IMMUNE TOLERANCE INDUCTION THERAPY IN SEVERE HEMOPHILIA A	Amal Abdi
ABS010	IDENTIFICATION OF TWO LARGE CHROMOSOMAL REARRANGEMENTS LEADING TO SEVERE HAEMOPHILIA A USING WHOLE F8 GENE SEQUENCING	Yohann Jourdy
ABS011	IMPROVED RECOGNITION OF B-DOMAIN DELETED FVIII IN PLASMA WITH A NEW COMMERCIALLY AVAILABLE VISULIZE F8PLUS ANTIGEN KIT	Ran Ni
ABS012	IN-HOUSE VALIDATION OF FACTOR VIII ACTIVITY FOR STANDARD AND EXTENDED HALF-LIFE PRODUCTS AND CORRELATION TO THROMBIN GENERATION ASSAYS	Cecilia Augustsson
ABS013	IS DEFINING SEVERE HAEMOPHILIA A FROM FVIII <1 IU/DL STILL RELEVANT IN 2021?	Clementine Wahl
ABS014	LABORATORY VALIDATION OF CRYOCHECK™ CHROMOGENIC FACTOR VIII ACROSS MULTIPLE COAGULATION ANALYZERS	Tara Quinton
ABS015	MHC CLASS I & II INDUCIBLE EXPRESSION ON IPS DERIVED ENDOTHELIAL CELLS PROVIDES A POTENTIAL CELLULAR MODEL TO STUDY FVIII IMMUNOGENICITY IN HEMOPHILIA A - PATIENTS	Heike Singer
ABS016	NEW PROBABLY PATHOGENIC VARIANTS IN TWO SPANISH PATIENTS WITH MILD HEMOPHILIA A: IMPORTANCE OF GENETIC ASSESSMENT.	Maria Civeira
ABS017	PHARMACOKINETIC DIFFERENCES IN HEMOPHILIA A BASED ON FVIII PRODUCT AND ON ASSAY TYPE	Lídia Costa
ABS018	ROTEM ASSAY CONDITIONS SENSITIVE TO CONCIZUMAB	Cecilia Augustsson
ABS019	THE IMPORTANCE OF GENETIC VARIANT DATABASES IN INTERPRETIVE REPORTING FOR HERITABLE BLEEDING DISORDERS	Ian Jennings
ABS020	APPLICATION OF PRIMARY HEPATOCYTE MODEL TO UNDERSTAND SPECIES TRANSLATABILITY AND MECHANISM OF ACTION OF AAV-MEDIATED GENE EXPRESSION	Su Liu
ABS022	HEMOPHILIA INTERNATIONAL ACCREDITATION TRAINING PLAN IN ERCIYES UNIVERSITY PEDIATRIC HEMATOLOGY CLINIC	Veysel Gök
ABS023	HEMOPHILIA, AN INTERESTING BIG DATA APPLICATION SCENARIO	Claudia Lucia Sossa
ABS024	SELECTIVE CHROMOGENIC MEASUREMENT OF FACTOR VIII ACTIVITY WITH AN ANTIBODY-BASED ASSAY	Alfred Weber
ABS025	SEVERE HEMOPHILIA (SEVH) PATIENT FOLLOW-UP DURING SARS COV-2 PANDEMIC – EXPERIENCE IN A HEMOPHILIA COMPREHENSIVE CARE CENTER (HCCC), COIMBRA, PORTUGAL	Catarina Guedes
ABS026	STAGES OF VIRAL INACTIVATION IN THE TECHNOLOGICACL SHEME OF PURIFICATION OF FACTOR VIII	Nataliia Shurko
ABS027	SUBCUTANEOUS MARZEPTACOG ALFA (ACTIVATED) IS EFFECTIVE FOR ON-DEMAND TREATMENT OF SPONTANEOUS BLEEDING IN HEMOPHILIA A RATS	Tom Knudsen
ABS028	SUBCUTANEOUS MARZEPTACOG ALFA ACTIVATED (MARZAA) IS EFFECTIVE FOR ON-DEMAND TREATMENT IN DOGS WITH HEMOPHILIA A	Howard Levy
ABS029	THE EVOLUTION OF A RESEARCH UNIT IN LA PAZ UNIVERSITY HOSPITAL DURING 6 YEARS	Tamara Cebanu
ABS031	TRANSPLACENTAL DELIVERY OF MATERNAL FACTOR VIII	Angelina Mimoun
ABS032	VON WILLEBRAND FACTOR (VWF) SUPPRESSES FVIII-CONTAINING IMMUNE COMPLEXES (FVIII-IC) BINDING TO COMPLEMENT COMPONENT 1Q BY ALTERING FVIII-IC CHARACTERISTICS	Olga Oleshko
ABS033	VWF-CONTAINING FVIII CONCENTRATES IMPROVE FVIII RECOVERY IN A MOUSE MODEL OF SEVERE HAEMOPHILIA WITH INHIBITORS	Maria Isabel Bravo
ABS034	7TH INTERIM ANALYSIS OF ANTIHEMOPHILIC FACTOR (RECOMBINANT) AND JOINT HEALTH IN PATIENTS WITH HEMOPHILIA A: AHEAD INTERNATIONAL	Kate Khair
ABS035	A CROSS-SECTIONAL STUDY: RENAL FUNCTIONS IN ADULTS AND CHILDREN WITH HAEMOPHILIA	Bulent Zulfikar
ABS036	A MULTINATIONAL PROSPECTIVE, NON-INTERVENTIONAL, POST-MARKET SURVEILLANCE STUDY FROM BELGIUM, GERMANY AND ITALY: SAFETY ANALYSIS OF THE USE OF RIX-FP IN PATIENTS WITH HAEMOPHILIA B	Giancarlo Castaman
ABS037	A PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODEL TO CHARACTERIZE BIVV001 ACTIVITY, A NEW CLASS OF FACTOR VIII (FVIII) WITH HIGH SUSTAINED FACTOR ACTIVITY	Binfeng Xia
ABS038	A RETROSPECTIVE REVIEW OF CLINICAL OUTCOMES IN FRENCH PATIENTS WITH HAEMOPHILIA A SWITCHING TO RVIII-SINGLECHAIN PROPHYLAXIS	Abel Hassoun
ABS039	A RETROSPECTIVE STUDY OF THE IMPACT OF SWITCHING PATIENTS WITH HAEMOPHILIA A TO RURIOCTOCOG ALFA PEGOL OR EMICIZUMAB IN US PRACTICE	Shawn X Sun
ABS040	A SYSTEMATIC APPROACH TO PROPHYLAXIS IN A SERIES OF THREE PREVIOUS UNTREATED PATIENTS WITH SEVERE HAEMOPHILIA B	Pollio Berardino
ABS041	ACCESSIBILITY TO TREATMENT OF BLEEDING DIATHESIS DURING COVID-19 PANDEMIC. “HOME DELIVERY” EXPERIENCE IN A GENERAL HOSPITAL IN SPAIN	Bolivar Díaz-Jordan
ABS042	ACQUIRED HEMOPHILIA ASSOCIATED WITH CONGENITAL FACTOR XI DEFICIENCY AND NEPHROTIC SYNDROME AND THE THERAPEUTIC CHALLENGE : PEDIATRIC CASE	Wassila Messadi
ABS043	AMT-060 GENE THERAPY IN ADULTS WITH SEVERE OR MODERATE-SEVERE HEMOPHILIA B CONFIRM STABLE FIX EXPRESSION AND SUSTAINED REDUCTIONS IN BLEEDING FOR UP TO 5 YEARS	Frank W G Leebeek
ABS044	AN AUDIT AND SURVEY OF THE ANNUAL PHYSIOTHERAPY REVIEW SERVICE IN A COMPREHENSIVE HAEMOPHILIA CARE CENTRE IN IRELAND	Mark Mcgowan
ABS045	ANAEMIA IN SEVERE HAEMOPHILIA: MOVING BEYOND IRON DEFICIENCY	Pedro Chorão
ABS046	ANALYSIS OF EXTENDED DOSING REGIMENS WITH RECOMBINANT COAGULATION FACTOR IX ALBUMIN FUSION PROTEIN (RIX-FP) IN ADULT AND PAEDIATRIC PATIENTS WITH HAEMOPHILIA B: A POPULATION PHARMACOKINETIC SIMULATION	William McKeand
ABS047	ANNUAL BLEEDS (AB) AND HEALTH-RELATED QUALITY OF LIFE (HRQOL) AMONG ADULTS WITH HAEMOPHILIA A (HA) RECEIVING PROPHYLAXIS	Lisa Young
ABS048	ANNUAL BLEEDS (AB) AND HEALTH-RELATED QUALITY OF LIFE (HRQOL)AMONG ADULTS WITH HAEMOPHILIA B	Leona Markson
ABS049	ANTITHROMBOTIC MANAGEMENT IN A SEVERE HAEMOPHILIA B PATIENT: CASE REPORT	Olga Benitez Hidalgo
ABS050	APPLICATION OF MULTI-CRITERIA DECISION ANALYSIS TO DETERMINE THE VALUE OF PROPHYLAXIS RELATIVE TO ON-DEMAND TREATMENT IN HAEMOPHILIA A AND EMICIZUMAB VERSUS REPLACEMENT THERAPY IN THE GREEK HEALTHCARE SETTING	George Gourzoulidis
ABS051	ASSESSING THE BLEEDING PHENOTYPE IN NON-SEVERE HEMOPHILIA BY USE OF THE ISTH BLEEDING ASSESSMENT TOOL (BAT)	Fabienne R. Kloosterman
ABS052	ASSESSMENT OF QUALITY OF LIFE OF PATIENTS IN KYRGYZSTAN USING THE PROBE TOOL	Declan Noone
ABS053	AUDIT OF 14 PATIENTS RECEIVING SUSOCTOCOG ALFA UNDER THE NHS ENGLAND COMMISSIONING POLICY	Louise Gray
ABS054	BAY 94-9027 PROPHYLAXIS SUSTAINS FACTOR VIII TROUGH LEVELS ABOVE 1% IN ALL TREATMENT REGIMENS IN PATIENTS WITH SEVERE HAEMOPHILIA A FROM PROTECT VIII	Maria Elisa Mancuso
ABS055	BAY 94-9027 PROVIDED EFFECTIVE LONG-TERM PROPHYLAXIS IN PEDIATRIC PATIENTS AGED ≥12 YEARS AT THE END OF THE PROTECT VIII KIDS EXTENSION STUDY, INDICATING CONSISTENT SAFETY OF TREATMENT INTO ADOLESCENCE	Gili Kenet
ABS056	BIOCHEMICAL MARKER RESEARCH IN HEMOPHILIC ARTHROPATHY: A SYSTEMATIC REVIEW	Eline Van Bergen
ABS057	BROAD PATIENT ELIGIBILITY AND LONG-TERM TOLERABILITY IN THE FIRST-IN-HUMAN GENE THERAPY STUDY OF BAY 2599023 IN SEVERE HAEMOPHILIA A	Francesca Ferrante
ABS058	CARE FOR PEOPLE WITH HAEMOPHILIA B: PERCEPTIONS OF SPECIALIST NURSES	Debra Pollard
ABS059	CAUSES OF HOSPITALIZATION IN PEOPLE WITH HAEMOPHILIA AT A PORTUGUESE HAEMOPHILIA CENTRE – FROM 2016 TO 2020, DID WE SEE A CHANGE?	Soraia Campaniço
ABS060	CHARACTERISTICS AND SELF-REPORTED OUTCOMES OF CHILDREN AND ADULTS WITH SEVERE HEMOPHILIA A FROM COLOMBIA	Liliana Torres
ABS061	CHARACTERIZATION OF CUBAN HEMOPHILIAC PATIENTS AT DIAGNOSIS IN A FOLLOW- PERIOD OF 11 YEARS	Dunia Castillo
ABS062	CHARACTERIZATION OF INHERITED COAGULATION DISORDERS PATIENTS AND COVID-19 INFECTION IN COLOMBIA	Ivan Perdomo-Amar
ABS063	CIRCUMCISION IN PATIENTS WITH HEMOPHILIA IN SOUTHERN TUNISIA CENTER	Maha Charfi
ABS064	CLEARANCE OF FIDANACOGENE ELAPARVOVEC VECTOR DNA IN PATIENTS WITH SEVERE OR MODERATELY SEVERE HEMOPHILIA B	Amit Chhabra
ABS065	CLINICAL AND LABORATORY PHENOTYPES OF PERSONS LIVING WITH HAEMOPHILIA IN SOUTHWEST NIGERIA	Titilope Adeyemo
ABS066	CLINICAL AND ULTRASOUND EVALUATION AGREEMENT TO DETECT EARLY JOINT DAMAGE IN PATIENTS WITH HAEMOPHILIA ON PROPHYLAXIS	Horacio Caviglia
ABS067	CLINICAL APPLICATION OF EXTENDED HALF-LIFE FACTOR VIII AND IX IN CHILDREN WITH HAEMOPHILIA A AND B	Athina Dettoraki
ABS068	CLINICAL BURDEN OF INHIBITORS IN HAEMOPHILIA B – USING DATA FROM CHESS II – A EUROPEAN REAL-WORLD DATA STUDY	Lisa Young
ABS069	CLINICAL EXPERIENCES WITH RECOMBINANT ACTIVATED FACTOR VII IN ACQUIRED HAEMOPHILIA A	Gianluca Sottilotta
ABS070	CLINICAL OUTCOMES IN PATIENTS WITH HAEMOPHILIA A AFTER SWITCHING TO RURIOCTOCOG ALFA PEGOL PROPHYLAXIS IN THE ATHN 2 STUDY	Janet Journeycake
ABS071	CLINICO-EPIDEMIOLOGICAL PROFILE OF PATIENTS WITH INHERITED COAGULOPATHIES AT A PAEDIATRIC HAEMOPHILIA CLINIC OF A TERTIARY CARE CENTRE IN GUJARAT	Khushboo Taneja
ABS072	COMORBIDITIES IN PATIENTS WITH HEMOPHILIA	Erick Arias
ABS073	COMPARATIVE READABILITY ANALYSIS OF INFORMATION ON EXERCISE FOR HEMOPHILIA PATIENTS	Hanna Moon
ABS074	COMPARISON OF FACTOR VIII UTILISATION AND BLEED RATES IN ITALIAN HAEMOPHILIA A PATIENTS WHO SWITCHED TO EXTENDED PROPHYLAXIS DOSING INTERVALS WITH RVIII-SINGLECHAIN	Maria Elisa Mancuso
ABS075	COMPARISON OF FUNCTIONAL INDEPENDENCE OF PAEDIATRIC HAEMOPHILIA PATIENTS OVER 5 YEARS OF ON-DEMAND RESCUE THERAPY	Khushboo Taneja
ABS076	CONGENITAL FACTOR DEFICIENCIES IN CHILDREN: A REPORT OF A SINGLE-CENTER EXPERIENCE	Wassila Messadi
ABS077	CONSEQUENCES OF STOPPING TREATMENT IN A PATIENT WITH HAEMOPHILIA A WITH INHIBITOR, DURING THE PANDEMIC.	Gabriela Susana sliba
ABS078	CROSS-ANALYSIS OF FRENCH HEALTHCARE PROFESSIONALS, PARENTS AND CHILDREN WITH HAEMOPHILIA A ON PROPHYLACTIC TREATMENT: THE APROCHE SURVEY.	Céline Falaise
ABS079	CURRENT STATUS OF CLINICAL TRIALS ON GENE THERAPY FOR HEMOPHILIA	Hanna Moon
ABS080	DEEP VEIN THROMBOSIS AFTER REMISSION IN A PATIENT WITH ACQUIRED HEMOPHILIA	Fatma Keklik Karadağ
ABS081	DENTAL HEALTH DURING COVID-19 PANDEMIC: TELE DENTISTRY HAEMOPHILIA MDQ EXPERIENCE	Gisela Dolabella
ABS082	DENTAL PROCEDURES FOR PATIENTS ON EMICIZUMAB– WHAT DO WE KNOW?	Aisyah Ahmad Fisal
ABS083	DEPRESSIVE SYMPTOMS AND ADHERENCE TO CLOTTING FACTOR REPLACEMENT THERAPY IN HAEMOPHILIA	Martina Bago
ABS084	DESIGN OF A POST-AUTHORIZATION LONG-TERM SAFETY STUDY FOR RURIOCTOCOG ALFA PEGOL IN PATIENTS WITH HEMOPHILIA A	Jingmei Zhang
ABS085	DIAGNOSIS AND MANAGEMENT OF HEMARTHROSIS AND HAEMOPHILIC ARTHROPATHY USING UNIFIED CLINICAL AND ULTRASOUND CRITERIA: PRELIMINARY RESULTS	Ana Chimeno-Hernández
ABS086	DIAGNOSIS OF CONGENITAL COAGULATION DISORDERS IN ASYMPTOMATIC PRE-OPERATIVE PATIENTS: USE OF THE ROSNER INDEX FOR THEIR DETECTION	Bolivar Díaz-Jordan
ABS087	EFFECTIVE PERIOPERATIVE MANAGEMENT WITH EXTENDED HALF-LIFE RFIX-FP REPLACEMENT THERAPY DURING A SURGICAL KNEE REPLACEMENT	Anna Kouramba
ABS088	EFFICACY AND SAFETY OF BAY 94-9027 PROPHYLAXIS IS SUSTAINED FOR ≥6 YEARS: OUTCOMES IN 22 PATIENTS IN THE PROTECT VIII EXTENSION STUDY	Mark T. Reding
ABS090	EFFICACY AND SAFETY OF HFVIII/VWF (VONCENTO®) CONCENTRATE IN PAEDIATRIC PATIENTS WITH VON WILLEBRAND DISEASE (VWD): THE FRENCH EXPERIENCE	Annie Harroche
ABS091	EFFICACY AND SAFETY OF HUMAN FIBRINOGEN CONCENTRATE IN PATIENTS WITH CONGENITAL FIBRINOGEN DEFICIENCY: RESULTS OF THE FORMA-02 AND FORMA-04 TRIALS	Bruce Schwartz
ABS092	EFFICACY OF RFIXFC VS RIX-FP FOR THE TREATMENT OF PATIENTS WITH HAEMOPHILIA B: MATCHING-ADJUSTED INDIRECT COMPARISON OF B-LONG AND PROLONG-9FP TRIALS	Jan Astermark
ABS093	EFFICACY OF RURIOCTOCOG ALFA PEGOL IN PATIENTS WITH SEVERE HAEMOPHILIA A AND CO-MORBIDITIES: A POST-HOC ANALYSIS OF THE PROLONG-ATE STUDY	Jorge Caicedo
ABS094	EMICIZUMAB PROPHYLAXIS IN A PATIENT WITH ACQUIRED HEMOPHILIA (TEXAS PROTOCOL): CASE REPORT	Miguel Escobar
ABS095	EMICIZUMAB PROPHYLAXIS IN ADULT AND PAEDIATRIC HAEMOPHILIA A PATIENTS WITHOUT INHIBITORS: A SINGLE CENTRE REAL WORLD EXPERIENCE	Patrizia Di Gregorio
ABS096	EMICIZUMAB PROPHYLAXIS IN HAEMOPHILIA A WITH AND WITHOUT INHIBITORS: REAL-WORLD DATA FROM SLOVENIA	Karla Rener
ABS097	EMICIZUMAB TREATMENT IN CHILDREN WITH HAEMOPHILIA A: EXPERIENCE OF A SINGLE GREEK HAEMOPHILIA CENTRE	Aikaterini Michalopoulou
ABS098	ENHANCED HALF-LIFE (EHL) VS. STANDARD HALF-LIFE (SHL) REPLACEMENT FACTORS IN HAEMOPHILIA A AND B: APPLICATION OF A HAEMOPHILIA VALUE FRAMEWORK	Mark Skinner
ABS099	ERADICATION OF CHRONIC HEPATITIS C INFECTION IN PERSONS WITH HEMOPHILIA IN NORTHERN SERBIA	Nebojša Rajić
ABS100	ETRANACOGENE DEZAPARVOVEC (AAV5-PADUA HFIX VARIANT) IN ADULTS WITH SEVERE OR MODERATE-SEVERE HEMOPHILIA B: TWO YEAR DATA FROM A PHASE 2B TRIAL	Annette von Drygalski
ABS101	EVALUATING BEST PRACTICE FOR THE CONSTRUCTION OF POPULATION PHARMACOKINETIC MODELS FOR PROPHYLAXIS WITH FACTOR CONCENTRATES IN HEMOPHILIA A AND B PATIENTS.	Tine MarieChristine Henriëtte Jeanine Goedhart
ABS102	EVALUATING THE ECONOMIC BURDEN ASSOCIATED WITH PROBLEM JOINTS, ACROSS MODERATE AND SEVERE HEMOPHILIA A, IN CHILDREN AND ADULTS: CHESS PAEDIATRICS AND CHESS II	Pratima Chowdary
ABS103	EVALUATION OF QUALITY OF LIFE ADULT PEOPLE WITH HEMOPHILIA FROM THE SOUTH OF TUNISIA	Olfa Kassar
ABS104	EXAMINATION AND VALIDATION OF A PATIENT-CENTRIC JOINT METRIC: “PROBLEM JOINT”; EMPIRICAL EVIDENCE FROM THE CHESS II DATASET	Tom Burke
ABS105	EXCELLENT REAL-WORLD EXPERIENCE AFTER PHARMACOKINETIC GUIDED SWITCH FROM STANDARD HALF –LIFE TO RURIOCTOCOG ALFA PEGOL	Olga Benitez Hidalgo
ABS106	EXIGENCY: KNOWLEDGE OF GENE THERAPY AMONG PARENTS OF CHILDREN WITH HAEMOPHILIA	Kate Khair
ABS107	EXPERIENCE OF SURGICAL ORTHOPEDIC TREATMENT IN A PATIENT WITH AN INHIBITORY FORM OF HEMOPHILIA A WHO IS BEING TREATED WITH EMICIZUMAB	Tatiana Polyanskaya
ABS108	EXPERIENCE ON THE USE OF RIX-FP IN PATIENTS WITH HAEMOPHILIA B: ANALYSIS FROM A PROSPECTIVE, NON INTERVENTIONAL, POST-MARKET SURVEILLANCE STUDY IN BELGIUM	Cedric Hermans
ABS109	EXPLORING PATIENTS’ PERCEPTION IN HEMOPHILIA A: DISEASE KNOWLEDGE AND BURDEN OF DISEASE, A CROSS-SECTIONAL STUDY IN COLOMBIA	Liliana Torres
ABS110	EXPLORING THE QUALITY OF LIFE AND SELF-REPORTED OUTCOMES OF PATIENTS WITH HEMOPHILIA A IN A CROSS-SECTIONAL STUDY IN COLOMBIA	Liliana Torres
ABS111	EXTENDED HALF-LIFE FACTOR IX TREATMENT IN HEMOPHILIA B PATIENTS: PRELIMINARY DATA FROM A REFERENCE CENTER	Olga Benitez Hidalgo
ABS112	FACTOR UTILISATION IN PATIENTS WITH HAEMOPHILIA A AFTER SWITCHING TO RURIOCTOCOG ALFA PEGOL IN THE ATHN 2 STUDY	Janet Journeycake
ABS113	FEIBA GLOBAL OUTCOME (FEIBA GO) STUDY: REAL-WORLD DATA IN PATIENTS WITH CONGENITAL HEMOPHILIA AND INHIBITORS	Cedric Hermans
ABS114	FOLLOW-UP ON A NOVEL ADENO ASSOCIATED VIRUS (AAV) GENE THERAPY (FLT180A) ACHIEVING NORMAL FIX ACTIVITY LEVELS IN SEVERE HEMOPHILIA B (HB) PATIENTS (B-AMAZE STUDY).	Pratima Chowdary
ABS115	HAEMOPHILIA A DISEASE AWARENESS AND EDUCATIONAL REQUIREMENTS IN ITALIAN EMERGENCY DEPARTMENT PHYSICIANS	Berardino Pollio
ABS116	HAEMOPHILIA AND ATRIAL FIBRILLATION - A CASE REPORT	Rita Serrano
ABS117	HAEMOPHILIA CARRIERS – A HIDDEN CHALLENGE IN CLINICAL SETTING: A CASE-REPORT	Sofia Teixeira
ABS118	HEALTH-RELATED QUALITY OF LIFE AFTER SUCCESSFUL HEPATITIS C VIRUS TREATMENT IN PEOPLE WITH HAEMOPHILIA: RESULTS FROM THE SIXTH HAEMOPHILIA IN THE NETHERLANDS SURVEY	Cas Isfordink
ABS119	HEMOPHILIA A PATIENT WITH HIGH THROMBOTIC AND HEMORRHAGIC RISK: A CASE REPORT	Francisco-Jose Lopez-Jaime
ABS120	HEMOPHILIA A PATIENTS WITH PREVIOUS JOINT BLEEDS AND CONSECUTIVE ARTHROPATHY MAY BENEFIT FROM HIGHER FVIII TROUGH LEVELS: POST HOC ANALYSIS OF THE PHASE 3 PROPEL TRIAL	Jerzy Windyga
ABS121	HEMOPHILIA TREATMENT CENTER OF STRASBOURG (FRANCE) DURING THE COVID-19 PANDEMIC	Dominique Desprez
ABS122	HEMOPHILIC PSEUDOTUMOR A RARE COMPLICATION OF HEMOPHILIA	Claudia Lucia Sossa
ABS123	HIGH DOSE OF EPTACOG BETA (FACTOR VIIA, RECOMBINANT) IS EFFECTIVE IN THE TREATMENT OF BLEEDING EPISODES REGARDLESS OF SEVERITY IN ADULT AND ADOLESCENT PATIENTS WITH HEMOPHILIA A OR B WITH INHIBITORS	Cédric Hermans
ABS124	HIGH INITIAL DOSING REGIMEN WITH EPTACOG BETA (FACTOR VIIA, RECOMBINANT) IS EFFICACIOUS IN PATIENTS WITH HEMOPHILIA A OR B WITH INHIBITORS UNDERGOING MAJOR SURGERY: RESULTS FROM THE PERSEPT 3 CLINICAL TRIAL	Cédric Hermans
ABS125	HOW I TREAT HAEMOPHILIA A PEDIATRIC PATIENTS WITH EMICIZUMAB: A SINGLE CENTER EXPERIENCE	Michele Schiavulli
ABS126	IMMUNE THROMBOCYTOPENIA REFRACTORY TO CORTICOID THERAPY SECONDARY TO COVID-19. A SINGLE-CENTRE EXPERIENCE	Bolivar Díaz-Jordan
ABS127	IMPROVEMENT IN PAIN AND LEVELS OF PHYSICAL ACTIVITY IN PATIENTS TREATED WITH RFIXFC: POST-HOC ANALYSIS OF B-LONG	Jan Astermark
ABS128	IMPROVEMENT IN PAIN-RELATED QUALITY OF LIFE IN PATIENTS WITH HAEMOPHILIA A TREATED WITH RFVIIIFC INDIVIDUALIZED PROPHYLAXIS: POST-HOC ANALYSIS FROM A-LONG	John Pasi
ABS129	IMPROVING DATA COLLECTION IN HEMOPHILIA PATIENTS IN SENEGAL	Saliou Diop
ABS130	IN SILICO COMPARISON OF PHARMACOKINETIC PROPERTIES OF THREE EXTENDED HALF-LIFE FACTOR IX CONCENTRATES	Laura H. Bukkems
ABS131	INDIRECT BURDEN ASSOCIATED WITH PRODUCTIVITY LOSS IN HAEMOPHILIA A & B – USING DATA FROM CHESS II – A EUROPEAN REAL-WORLD DATA STUDY	Lisa Young
ABS132	INDIRECT COMPARISON OF ANNUALISED BLEEDING RATE AND ANNUAL CONSUMPTION BETWEEN EXTENDED HALF-LIFE RFVIII PRODUCTS SHOWS DIFFERENCES IN CONSUMPTION WITH SIMILAR OUTCOME	Parth Vashi
ABS133	INHIBITORS IN SEVERE HEMOPHILIA A: 15-YEAR EXPERIENCE	wassila messadi
ABS134	INSIGHT INTO THE PERSISTENT CLINICAL BURDEN UNDERLYING PROBLEM JOINTS, PAIN, AND BLEEDING, IN ADULTS FROM ACROSS EUROPE WITH HAEMOPHILIA A AND B: THE CHESS II STUDY	Tom Burke
ABS135	INTERDISCIPLINARY INTERACTION IN COVID 19 PANDEMIC. BEYOND THE DISTANCE	Gabriela Susana Sliba
ABS136	INTERIM DATA FROM A CHART REVIEW STUDY OF PATIENTS WITH HAEMOPHILIA A WITH INHIBITORS TREATED WITH RECOMBINANT FACTOR VIII FC FUSION PROTEIN (RFVIIIFC) FOR IMMUNE TOLERANCE INDUCTION	Robert Klamroth
ABS137	INVASIVE SURGERY IN HAEMOPHILIA - ONE YEAR EXPERIENCE	Cristina Emilia Ursu
ABS138	JOINT STATUS OF PATIENTS WITH NON-SEVERE HEMOPHILIA A	Anne-Fleur Zwagemaker
ABS139	LONGER-TERM EFFICACY AND SAFETY OF CONCIZUMAB PROPHYLAXIS IN PATIENTS WITH SEVERE HAEMOPHILIA A WITHOUT INHIBITORS: RESULTS FROM THE EXTENSION PART OF THE PHASE 2 EXPLORER5 TRIAL	Hermann Eichler
ABS140	LONGITUDINAL SAFETY AND EFFICACY ANALYSIS OF RIX-FP IN ADULT PATIENTS WITH HAEMOPHILIA B TREATED ON A 21-DAY PROPHYLAXIS REGIMEN	Ingrid Pabinger
ABS141	LOW IMMUNOGENICITY OF EMICIZUMAB IN PERSONS WITH HAEMOPHILIA A	Christophe Schmitt
ABS142	LOW-DOSE IMMUNE TOLERANCE INDUCTION THERAPY IN SEVERE HEMOPHILIA A CHILDREN WITH HIGH-TITER INHIBITOR	Mohssen Saleh Elalfy
ABS143	MANAGEMENT OF ACQUIRED HEMOPHILIA A (AHA) PRESENTING IN PEDIATRIC AGE	Catarina Guedes
ABS144	MANAGEMENT OF MAJOR ABDOMINAL SURGERY IN AN ADOLESCENT PATIENT WITH SEVERE HAEMOPHILIA A AND FVIII INHIBITOR ON EMICIZUMAB	Alice Wilkinson
ABS145	MANAGEMENT OF PATIENTS WITH HAEMOPHILIA A PRESENTING AT EMERGENCY DEPARTMENTS IN ITALY	Alessandra Borchiellini
ABS146	MANAGING ACQUIRED BLEEDING COAGULOPATHIES: RECOMMENDATIONS FROM THE PORTUGUESE CONSENSUS ON COAGULOPATHIC BLEEDING MANAGEMENT (CCBM)	Manuela Gomes
ABS147	MONITORING OF THE JOINT HEALTH OF PATIENTS WITH HEMOPHILIA IN SPAIN. INITIAL ANALYSIS OF THE JOINT US PROJECT	María Teresa Álvarez-Román
ABS148	MYOCARDIAL INFARCTION AND SEVERE HAEMOPHILIA B: A CHALLENGING BALANCED MANAGEMENT	Cláudia Vaz
ABS149	ONGOING VALIDATION OF A NEW DISEASE-SPECIFIC INSTRUMENT ASSESSING FUNCTIONAL ABILITIES IN PATIENTS WITH HAEMOPHILIA: THE HEMOPHILIA FUNCTIONAL ABILITY SCORING TOOL (HEMO-FAST)	Virginie Barbay
ABS150	PAIN AND QUALITY OF LIFE AMONGST ELDERLY AND MILD PATIENTS WITH HAEMOPHILIA: A NATIONAL BELGIAN SURVEY STUDY	Valérie-Anne Chantrain
ABS151	PAIN BEHAVIOR STRATEGIES IN PATIENTS WITH HAEMOPHILIA: A SYSTEMATIC REVIEW	Anthe Foubert
ABS152	PAIN MANAGEMENT PROTOCOL: A KEY TOOL TO IMPROVE PATIENTS’ QUALITY OF LIFE IN A CONGENITAL COAGULOPATHIES REFERENCE CENTER	Diana Cibele
ABS153	PATIENT AND HEALTHCARE PROFESSIONAL VIEWS ON A PERSONAL HEALTH RECORD IN HAEMOPHILIA CARE: A QUALITATIVE STUDY	Martijn Brands
ABS154	PATIENT RECEIVING PROPHYLAXIS WITH CONCIZUMAB AND UNDERGOING MINOR SURGERY: A CASE REPORT	Francisco-Jose Lopez-Jaime
ABS157	PERIOPERATIVE MANAGEMENT OF PATIENTS WITH SEVERE HAEMOPHILIA A WITH RECOMBINANT FACTOR VIII FC FUSION PROTEIN (RFVIIIFC)	Sara Bocchinfuso
ABS158	PERIOPERATIVE MANAGEMENT WITH ALBUTREPENONACOG ALFA (IDELVION®) IN A NEWBORN AFFECTED WITH MILD/MODERATE HAEMOPHILIA B. CASE REPORT.	María Fernanda Martínez García
ABS159	PHARMACOKINETIC ANALYSIS IN PATIENTS WITH HEMOPHILIA A SEVERE IN PROPHYLAXIS WITH RURIOCTOCOG ALFA PEGOL	Francisco-Jose Lopez-Jaime
ABS160	PHARMACOKINETIC DRUG EVALUATION OF STANDARD HALF-LIFE AND EXTENDED HALF-LIFE FACTOR VIII IN PATIENTS WITH HEMOPHILIA A	Francisco-Jose Lopez-Jaime
ABS161	PHARMACOKINETIC IMPLICATIONS OF DOSING EMICIZUMAB BASED ON VIAL SIZE: A SIMULATION STUDY	Jacky Yu
ABS162	POSTIVE IMPACT OF SWITCHING PREVIOUSLY TREATED PATIENTS (PTPS) TO RECOMBINANT FACTOR VIII FC FUSION PROTEIN (RFVIIIFC) IN THE ANNUALIZED BLEEDING RATE (ABR): REAL WORLD EXPERIENCE	Olga Benitez Hidalgo
ABS163	PREDICTIVE MODELLING IDENTIFIES RESPONSE TO FIXED DOSE N8-GP PROPHYLAXIS IN THE FIRST WEEKS OF TREATMENT AS A PREDICTOR OF LONG-TERM OUTCOMES	Pratima Chowdary
ABS164	PREVALENCE OF VIRAL INFECTIONS IN PATIENTS WITH HEMOPHILIA	Maha Charfi
ABS165	PROPHYLAXIS VS ON-DEMAND TREATMENT IN MODERATE HAEMOPHILIA A PATIENTS WITH NO INHIBITORS IN EU5	Sarah Brown
ABS166	PROPHYLAXIS WITH EMICIZUMAB IN HAEMOPHILIA A PATIENTS WITH INHIBITORS: DATA OF A PORTUGUESE CONGENITAL COAGULOPATHIES REFERENCE CENTRE	Marcos Sousa
ABS167	PSOAS MUSCLE HEMATOMA : A SINGLE CENTER EXPERIENCE	Maha Charfi
ABS168	RACIAL DIFFERENCES IN SEVERITY AND INHIBITOR PREVALENCE OF HEMOPHILIA A	Hanna Moon
ABS169	RATIONALE AND STUDY DESIGN FOR A PROSPECTIVE 48-MONTH, MULTI-CENTRE, OBSERVATIONAL STUDY EVALUATING LONG-TERM EFFECTIVENESS OF RFVIIIFC ON JOINT HEALTH – THE A-MORE STUDY	Stefan Lethagen
ABS170	REAL WORLD BLEEDING RATES OVER 7 YEARS OF ANTIHEMOPHILIC FACTOR (RECOMBINANT) IN PATIENTS WITH HEMOPHILIA A AND TARGET JOINTS: AHEAD INTERNATIONAL	Margareth C. Ozelo
ABS171	REAL WORLD EXPERIENCE OF PORCINE FVIII USE IN COMPLEX PELVIC SURGERY AND ACQUIRED HAEMOPHILIA A: CASE REPORT AND MULTI-DISCIPLINARY TEAM REFLECTION.	Kayleigh McCloskey
ABS172	REAL WORLD PROPHYLAXIS WITH RECOMBINANT FACTOR IX FC FUSION PROTEIN (RFIXFC) – LONGITUDINAL FOLLOW UP IN A NATIONAL COHORT	Mairead O'Donovan
ABS173	REAL‐LIFE EXPERIENCE IN SWITCHING TO A NEW EXTENDED HALF‐LIFE FIX PRODUCT AT A PORTUGUESE HAEMOPHILIA CENTRE: FIRST IMPRESSIONS AND ESTIMATED RESULTS	Cristina Catarino
ABS174	REAL-WORLD CLINICAL OUTCOMES IN PEOPLE FROM ACROSS EUROPE WITH SEVERE HAEMOPHILIA B RECEIVING FIX PROPHYLAXIS: AN ANALYSIS OF CHESS II	Nanxin (Nick) Li
ABS175	REAL-WORLD EFFECTIVENESS AND USAGE OF RECOMBINANT FACTOR IX FC FUSION PROTEIN (RFIXFC) FOR MANAGEMENT OF MAJOR/MINOR SURGERIES IN PATIENTS WITH HAEMOPHILIA B (HB) IN FRANCE: RESULTS FROM THE ONGOING B-SURE STUDY	Elena Santagostino
ABS176	REAL-WORLD EFFICACY OF EMICIZUMAB PROPHYLAXIS IN PATIENTS WITH SEVERE HAEMOPHILIA A WITHOUT INHIBITORS: A REPORT FROM THE UK HAEMOPHILIA CENTRE DOCTORS’ ORGANISATION	Caroline Wall
ABS177	REAL-WORLD EXPERIENCE AFTER SWITCHING TO RIX-FP PROPHYLAXIS IN A PATIENT WITH HAEMOPHILIA B IN THE CONTEXT OF THE COVID-19 PANDEMIC	Bolívar Luis Díaz Jordán
ABS178	REAL-WORLD EXPERIENCE OF PATIENTS WITH HAEMOPHILIA A SWITCHING TO RVIII-SINGLECHAIN PROPHYLAXIS IN SPAIN	Ramiro José Nuñez-Vazquez
ABS179	REAL-WORLD EXPERIENCE OF RIX-FP IN TWO PREVIOUSLY UNTREATED PAEDIATRIC PATIENTS WITH SEVERE HAEMOPHILIA B IN ITALY	Michele Schiavulli
ABS180	REAL-WORLD EXPERIENCE OF SWITCHING FROM SHL-RFIX TO EHL-RFIXFC IN MODERATE AND SEVERE HAEMOPHILIA B PATIENTS: A RETROSPECTIVE ANALYSIS FROM TWO BELGIAN CENTERS	Kathelijne Peerlinck
ABS181	REAL-WORLD SAFETY AND EFFECTIVENESS OF RECOMBINANT B-DOMAIN–DELETED PORCINE-SEQUENCE FACTOR VIII FOR ACQUIRED HEMOPHILIA A	Wolfgang Miesbach
ABS182	REATMENT OF NON-INHIBITOR PATIENTS WITH HEMOPHILIA A WITH EMICIZUMAB PROPHYLAXIS DURING THE COVID-19 PANDEMIC - MACEDONIAN CLINICAL EXPERIENCE	Irina Panovska-Stavridis
ABS183	RECOMBINANT FACTOR VIII-SINGLECHAIN (LONOCTOCOG ALPHA) AS SURGICAL PROPHYLAXIS IN PATIENTS WITH HAEMOPHILIA A. EXPERIENCE OF A REFERENCE HEMOPHILIA CENTER.	Olga Benitez Hidalgo
ABS184	RESULTS FROM A 52-WEEK, PROSPECTIVE, NONINTERVENTIONAL STUDY OF INDIVIDUALS WITH SEVERE HAEMOPHILIA A RECEIVING PROPHYLAXIS: RATES OF BLEEDING, FVIII USE, AND QUALITY OF LIFE	Gili Kenet
ABS185	RESULTS FROM A PHASE 1/2 SAFETY AND DOSE ESCALATION STUDY OF TAK-754, AN AAV8 VECTOR WITH A CODON-OPTIMIZED B-DOMAIN–DELETED FACTOR VIII TRANSGENE IN SEVERE HEMOPHILIA A	John Chapin
ABS186	RETROSPECTIVE ANALYSIS OF RVIII-SINGLECHAIN AND OTHER COMMONLY USED RECOMBINANT FVIII PRODUCTS COMPARING PROPHYLAXIS TREATMENT REGIMENS AND ASSOCIATED CLINICAL OUTCOMES IN HAEMOPHILIA A PATIENTS IN ITALY	Maria Elisa Mancuso
ABS187	REVISION SEVERAL MONTHS AFTER THE PANDEMIA: THE COLLATERAL EFFECTS IN A CLINICAL TRIALS UNIT	Sara García-Barcenilla
ABS188	RISK MITIGATION STRATEGY FOR CONCIZUMAB CLINICAL TRIALS RE-INITIATION AFTER PAUSE DUE TO NON-FATAL THROMBOTIC EVENTS	Stephanie Seremetis
ABS189	ROLE OF POINT OF CARE ULTRASOUND IN THE EARLY DIAGNOSIS OF HAEMOPHILIC ARTHROPATHY AND INDIVIDUALIZATION OF TREATMENT IN CHILDREN WITH HAEMOPHILIA: A PRELIMINARY STUDY FROM A SINGLE HAEMOPHILIA COMPREHENSIVE CARE CENTER IN GREECE	Helen Pergantou
ABS190	RURIOCTOCOG ALFA PEGOL PK-TAILORED PROPHYLAXIS MAY REDUCE BLEED RISK DURING PHYSICAL ACTIVITIES VS EMICIZUMAB: MICROSIMULATION WITH INDIVIDUAL PATIENT DATA FROM THE PROPEL PHASE 3 TRIAL	Shawn X. Sun
ABS191	SAFETY AND EFFICACY OF BAY 94-9027 PROPHYLAXIS IN PATIENTS WITH SEVERE HAEMOPHILIA A: INTERIM RESULTS OF A POST-MARKETING INTERVENTIONAL STUDY	Pål Andrè Holme
ABS192	SAFETY AND EFFICACY OF EMICIZUMAB IN PERSONS WITH HAEMOPHILIA A WITH/WITHOUT FVIII INHIBITORS: POOLED DATA FROM FOUR PHASE III STUDIES (HAVEN 1–4)	Michael U. Callaghan
ABS193	SAFETY AND EFFICACY OF HIGH-DOSE, PLASMA-DERIVED FVIII IN PATIENTS WITH ACQUIRED HAEMOPHILIA A	Silvia Horneff
ABS195	SOCIAL MEDIA AS A TOOL FOR PROVIDING DENTAL CARE AND RECOMMENDATION TO BLEEDING DISORDERS POPULATION DURING COVID-19 PANDEMIC	Laura Isidro Olan
ABS196	SOCIOECONOMIC FACTORS AND FRECUENCY OF ORAL HYGIENE IN PEOPLE WITH BLEEDING DISORDERS	Laura Isidro Olan
ABS198	TAILORED PROPHYLAXIS IN CHILDREN WITH SEVERE HEMOPHILIA A: FOUR-YEAR IRANIAN STUDY	Shadi Tabibian
ABS199	THE CLINICAL PHENOTYPE OF PATIENTS WITH NON-SEVERE HEMOPHILIA A AND B	Anne-Fleur Zwagemaker
ABS200	THE HIDDEN JOINT IN PATIENTS WITH HEMOPHILIA ON PROPHYLAXIS	Horacio Caviglia
ABS201	THE IMPACT OF A BASIC TRAINING ON KNOWLEDGE ABOUT THE DISEASE IN COLOMBIAN PATIENTS WITH HEMOPHILIA (PWH)	Liliana Torres
ABS202	THE MANAGEMENT OF RENAL DISEASE IN HAEMOPHILIA	Emília Araújo
ABS203	THE WORLD FEDERATION OF HEMOPHILIA GENE THERAPY REGISTRY	Donna Coffin
ABS204	TREATMENT OUTCOMES IN PATIENTS WITH SEVERE HEMOPHILIA B IN THE NORDIC REGION, THE B-NORD STUDY	Kristina Kihlberg
ABS205	TREATMENT PREFERENCES IN HEMOPHILIA: RESULTS FROM A TARGETED LITERATURE REVIEW	Jessie Sutphin
ABS206	UPTAKE OF EMICIZUMAB FOR PROPHYLAXIS IN CHILDREN WITH SEVERE HAEMOPHILIA A <12 YEARS OF AGE IN THE UK.	Mary Mathias
ABS207	USE OF DESMOPRESSIN IN THE TREATMENT OF BLEEDING IN NON-SEVERE HEMOPHILIA A	Fabienne R. Kloosterman
ABS208	WFH SURVEY ON THE EFFECT OF THE COVID-19 PANDEMIC ON THE GLOBAL BLEEDING DISORDERS COMMUNITY	Salome Mekhuzla
ABS209	WORLD BLEEDING DISORDERS REGISTRY SHOWCASES DISPARITIES IN HEMOPHILIA CARE AROUND THE WORLD	Emily Ayoub
ABS210	ZERO INCIDENCE OF FACTOR VIII INHIBITORS AND SUCCESSFUL HAEMOSTATIC RESPONSE IN PREVIOUSLY FACTOR VIII-TREATED HAEMOPHILIA A PATIENTS SWITCHING TO TUROCTOCOG ALFA IN A NON-INTERVENTIONAL STUDY	Carmen Escuriola-Ettingshausen
ABS211	CHARACTERISTICS OF VON WILLEBRAND DISEASE PATIENTS: RESULTS FROM SOUTHERN TUNISIA REGISTRY	Rahma Mallek
ABS212	DELIVERY MANAGEMENT OF A TYPE 3 VON WILLEBRAND DISEASE WITH A POTENTIAL ALLO-IMMUNISATION WITH RECOMBINANT VWF, VONICOG ALPHA, AND FACTOR VIII CONCENTRATES.	Floriane Devaux
ABS213	REALIZING THE IMPORTANCE OF GENETIC STUDIES IN PATIENTS WITH CONGENITAL BLEEDING DISORDERS	Soraia Campaniço
ABS214	ACQUIRED VON WILLEBRAND SYNDROME ASSOCIATED WITH CONTINUOUS-FLOW LEFT VENTRICULAR ASSIST DEVICE: DIFFERENCES BETWEEN AXIAL- AND CENTRIFUGAL-FLOW PUMPS	Hanna Moon
ABS215	ACQUIRED VON WILLEBRAND SYNDROME: A REPORT OF CASE SERIES	Ana Isabel Pimentel Feliciano
ABS216	COVID-19 IN VON WILLEBRAND DISEASE TYPE 3 CHILD	Raneem Tarawah
ABS217	DESMOPRESSIN RESPONSE DEPENDS ON GENETIC VARIANTS IN TYPE 1 AND TYPE 2 VON WILLEBRAND DISEASE PATIENTS	Ferdows Atiq
ABS218	EDUCATION VERSUS INTERVENTION: TACKLING GUM BLEEDING IN PEOPLE WITH LOW VON WILLEBRAND FACTOR LEVELS.	Sviatlana Anishchuk
ABS220	EPIDEMIOLOGY OF VON WILLEBRAND DISEASE: A SYSTEMATIC REVIEW	Ping Du
ABS221	EXPLORING THE PRESENCE AND IMPACTS OF GUM BLEEDING IN VON WILLEBRANDS DISEASE – WHAT LIES BENEATH THE DATA?	Declan Noone
ABS222	IMPACT OF VON WILLEBRAND DISEASE ON WOMEN’S HEALTH OUTCOMES: A MATCHED COHORT DATABASE STUDY	Ping Du
ABS223	LOW RISK OF BLEEDING IN PREGNANT WOMEN WITH VONWILLEBRAND DISEASE IS RELATED TO THE NATURAL INCREASE OF VONWILLEBRAND AND VIII FACTOR	PILAR VELARDE LOPEZDEAYALA
ABS224	LOW VON WILLEBRAND ANTIGEN LEVELS IN PATIENTS PRESENTING WITH EASY BRUISING AND MILD BLEEDING	Mehmet Baysal
ABS226	MANAGEMENT OF MENORRHAGIA IN PATIENTS WITH VON WILLEBRAND DISEASE	Rahma Mallek
ABS227	MANAGEMENT OF PATIENTS WITH VON WILLEBRAND DISEASE UNDERGOING PROPHYLAXIS FOR GASTROINTESTINAL BLEEDING: RESULTS OF A POST-MARKETING STUDY WITH A HIGH-PURITY PLASMA-DERIVED VON WILLEBRAND FACTOR	Jenny Goudemand
ABS228	MANAGEMENT OF PATIENTS WITH VON WILLEBRAND DISEASE UNDERGOING PROPHYLAXIS FOR JOINT BLEEDING: RESULTS OF A POST-MARKETING STUDY WITH A HIGH-PURITY PLASMA-DERIVED VON WILLEBRAND FACTOR.	Jenny Goudemand
ABS229	PHARMACOKINETIC MODELING OF THE VON WILLEBRAND FACTOR - FACTOR VIII INTERACTION IN PERIOPERATIVE VON WILLEBRAND DISEASE PATIENTS	Laura H. Bukkems
ABS230	SURGICAL PROPHYLAXIS OUTCOMES IN PATIENTS WITH INHERITED VON WILLEBRAND´S DISEASE IN A SINGLE CENTER	PILAR VELARDE LOPEZDEAYALA
ABS231	USE OF VONICOG ALPHA DURING A TRANSCATHETER AORTIC VALVE IMPLANTATION IN A PATIENT WITH ACQUIRED VON WILLEBRAND SYNDROME: ABOUT A CASE	Dominique Desprez
ABS232	A CHILD WHO DEVELOPED LUPUS ANTICOAGULANT HYPOPROTHROMBINEMIA SYNDROME AFTER VIRAL GASTROENTERITIS	Veysel Gök
ABS233	ACQUIRED COAGULOPATHY AS A PRIMARY MANIFESTATION OF HEMATOLOGICAL MALIGNANCIES: TWO CASE REPORTS	Soraia Campaniço
ABS234	CHALLENGING POST-PARTUM ACQUIRED HAEMOPHILIA A: IS IT POSSIBLE A SECOND PREGNANCY WITHOUT RELAPSE ? A CASE REPORT	Mariaconcetta Russo
ABS235	CHARACTERISTICS OF GLANZMANN THROMBASTENIA PATIENTS IN SOUTHERN TUNISIA CENTER	Maha Charfi
ABS236	CLINICAL CHARACTERIZATION AND IDENTIFICATION OF RARE GENETIC VARIANTS IN ATYPICAL HEMOLYTIC UREMIC SYNDROME: A SWEDISH RETROSPECTIVE OBSERVATIONAL STUDY	Alexander Åkesson
ABS237	COAGULOPATHY ASSOCIATED WITH EXTRACORPOREAL MEMBRANE OXYGENATION IN COVID-19 PATIENTS: A SINGLE CENTER STUDY.	Diana Cibele
ABS238	COLON RESTORATION AND REMOVAL OF STOMA IN PATIENT WITH CONGENITAL FACTOR X(TEN) DEFICIENCY	Bledi Kalaja
ABS239	COMPARATIVE ASPECT OF HEMORRHAGIC SYMPTOMATOLOGY IN INHERITED PLATELET DISORDER IN WESTERN ALGERIA	Reda Messaoudi
ABS240	CONGENITAL FACTOR V DEFICIENCY WITH INTRACRANIAL (ICH) IN TWO SIBLINGS FROM OMAN – A DISORDER IN NEED OF A SPECIFIC CONCENTRATE.	Alyaa Al Mughairy
ABS241	CONGENITAL FACTOR VII DEFICIENCY IN SOUTH OF TUNISIA: CLINICAL, BIOLOGICAL AND THERAPEUTIC FEATURES	Manel Ghorbel
ABS242	CORRELATION STUDY BETWEEN THE ISTH-BAT BLEEDING SCORE AND THE HEMOGLOBIN LEVEL DURING INHERITED PLATELET DISORDER	Reda Messaoudi
ABS243	DIAGNOSIS AND MANAGEMENT OF ACQUIRED FACTOR XI DEFICIENCY IN SYSTEMIC LUPUS ERYTHEMATOSUS	Bella Madan
ABS244	EVALUATION OF THE ISTH-BAT AND PBQ BLEEDING ASSESSMENT TOOLS IN CHILDREN WITH A SUSPECTED HEREDITARY COAGULATION DISORDER	Anne-Fleur Zwagemaker
ABS245	EVALUATION OF THERAPEUTIC OPTIONS FOR PATIENTS WITH FACTOR VII DEFICIENCY USING GLOBAL COAGULATION ASSAYS	María Isabel Rivas Pollmar
ABS246	FACTOR XI DEFICIENCY IN PREGNANT WOMEN: A CASE-SERIES FROM A NEW YORK CITY HOSPITAL	Guilherme Sacchi De Camargo Correia
ABS247	GASTROINTESTINAL ANGIODYSPLASIA IN TWO CHILDREN WITH GLANZMANN THROMBASTHENIA	Raghad Tarawah
ABS248	GLANZMANN THROMBASTHENIA AND SUSPICION OF COVID-19 : ABOUT A PEDIATRIC CASE IN STRASBOURG	Dominique Desprez
ABS249	HEALTH RELATED QUALITY OF LIFE IN PATIENTS WITH HEMOSTASIS DISEASE IN SOUTH OF TUNISIA	Maha Charfi
ABS250	INFLUENCE OF PARA-SULFONATO-CALIX[N]ARENES ON SELECTED COMPONENTS OF COAGULATION SYSTEM	Roza Aisina
ABS251	INHERITED RARE FACTOR DEFICIENCIES: SINGLE CENTER EXPERIENCE	Basak Koc
ABS252	LIGNEOUS CONJUNCTIVITIS AND USE OF HUMAN PLASMINOGEN DROPS: THE ITALIAN EXPERIENCE	Maria Teresa Sartori
ABS253	LIVER TRANSPLANTATION IN A PATIENT WITH SEVERE CONGENITAL FACTOR VII DEFICIENCY USING ONLY ONE ADMINISTRATION OF RECOMBINANT FACTOR VIIA: A CASE REPORT	Emmanuelle De Raucourt
ABS254	LUPUS ANTICOAGULANT-HYPOPROTHROMBINEMIA SYNDROME: LOOK AND YOU WILL FIND IT!	Jose Agustín Rodríguez-Alén
ABS255	MUTATION SPECTRUM OF F11 GENE IN HEMOPHILIA C PATIENTS FROM RUSSIA	Olesya Pshenichnikova
ABS256	MUTATION SPECTRUM OF F12 GENE IN PATIENTS WITH HAGEMAN FACTOR DEFICIENCY IN RUSSIA.	Ekaterina Demidova
ABS257	MUTATIONS IN ADAMTS13 GENE IN PATIENTS WITH THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) IN RUSSIA	Julia Poznyakova
ABS258	PATIENTS WITH CONGENITAL BLEEDING DISORDERS AND COVID-19 : FROM ONE CENTRE IN ALGIERS, ALGERIA	Nawel Ferroudj
ABS259	RARE BLEEDING DISORDERS IN PEDIATRICS: A SINGLE CENTER EXPERIENCE	Mohamed Elshinawy
ABS260	SEVERE MENORRHAGIA AND GLANZMANN’S THROMBASTHENIA. THE CHALLENGE OF MORE INVASIVE PROCEDURES. A CASE-REPORT	Diana Carneiro-Leão
ABS261	SEVERE PREKALLIKREIN DEFICIENCY: A MASKED RARE DISEASE IN PANDEMIC TIMES	Sofia Teixeira
ABS262	STUDY OF THE SENSITIVITY OF HEMORRHAGIC SCORES (ISTH-BAT, ESS AND PBAC) IN THE SCREENING OF INHERITED PLATELET DISORDER	Reda Messaoudi
ABS263	SURGICAL EXPERIENCE ON PATIENTS WITH BLEEDING DISORDERS IN HOSPITAL DE BRAGA	Joana Curvelo Cabral
ABS264	THE DIVERSITY OF ACQUIRED VON WILLEBRAND SYNDROME (AVWS). EXPERIENCE OF A HOSPITAL CENTRE.	María Irene Nuevo López
ABS265	THE EXAMINATION OF PLATELET WHOLE-MOUNT PREPARATIONS IN PATIENTS WITH GLANZMANN THROMBASTHENIA (CD41<1%)	Andrey Mamaev
ABS266	THROMBOSIS IN INHERITED FIBRINOGEN DISORDERS	Elena Yakovleva
ABS267	THROMBOTIC MICROANGIOPATHY (TMA) ASSOCIATED WITH COVID-19 INFECTION TREATED WITH ECULIZUMAB	ISABEL HERNANDEZ DE CASTRO
ABS268	TREATMENT OF PATIENTS WITH RARE BLEEDING DISORDERS IN THE NETHERLANDS: REAL-LIFE DATA FROM THE RBIN STUDY	D.P.M.S.M. Maas
ABS269	VALUE OF ROUTINE PREOPERATIVE HEMOSTASIS TESTING BEFORE ELECTIVE SURGERY IN DETECTING NEW CASES OF DISORDERS IN THE HEMOSTATIC SYSTEM RESULTS FROM REGIONAL CENTER FOR TRANSFUSION MEDICINE STIP	Meri Shorova
ABS270	A SINGLE UK PAEDIATRIC HAEMOPHILIA COMPREHENSIVE CARE CENTRE EXPERIENCE OF A NURSE-LED HAEMOPHILIA CLINIC FOR FEMALES WITH FACTOR VIII OR IX DEFICIENCY	Sarah Pool
ABS271	ESTABLISHMENT OF THE ESTONIAN NATIONAL REGISTRY OF PATIENTS WITH BLEEDING DISORDERS	Maria Hytti
ABS272	THE USE OF PARAFILM TO PREVENT CVADS INFECTION IN PATIENT WITH SEVERE FACTOR X DEFICIENCY	Shaun emmitt
ABS273	ASSOCIATION BETWEEN RANGE OF MOTION DEFICIT AND MUSCLE STRENGTH IN PATIENTS WITH HEMOPHILIC KNEE ARTHROPATHY.	Rubén Cuesta-Barriuso
ABS274	COVID-19 PANDEMIC LOCKDOWN: MUSCULOSKELETAL CHANGES IN PATIENTS WITH HEMOPHILIC ARTHROPATHY. AN OBSERVATIONAL STUDY.	Rubén Cuesta-Barriuso
ABS277	FEASIBILITY OF A RECENTLY INTRODUCED PHYSIOTHERAPY ASSESSMENT BATTERY INTO HEMOPHILIA CARE	Anne Juanós Solé
ABS278	FEASIBILITY OF BLENDED THERAPY: FACE-TO-FACE PHYSIOTHERAPY COMBINED WITH TABLET-BASED EXERCISES	Andrea Bärlocher
ABS279	HOW DOES EXERCISE CAPACITY IN BOYS WITH HAEMOPHILIA COMPARE WITH AGED MATCHED BOYS WITH CYSTIC FIBROSIS?	Melanie Bladen
ABS282	POSTURAL BALANCE EVALUATION IN HAEMOPHILIA	Stephanie Taylor
ABS284	REDUCING THE BURDEN OF HAL AND PEDHAL ASSESSMENT	Isolde Kuijlaars
ABS285	RELATIONSHIP BETWEEN JOINT HEALTH AND PRESSURE PAIN THRESHOLD, AND ISOMETRIC FORCE GENERATION AND MUSCLE ACTIVATION IN PATIENTS WITH HEMOPHILIC ANKLE ARTHROPATHY.	Rubén Cuesta-Barriuso
ABS286	RELATIONSHIP OF JOINT DAMAGE AND PRESSURE PAIN THRESHOLD IN QUADRICEPS MUSCLE ACTIVATION IN PATIENTS WITH HEMOPHILIC KNEE ARTHROPATHY.	Rubén Cuesta-Barriuso
ABS288	CINDERELLA: THE LIVED EXPERIENCE OF BLEEDING AMONG THE WOMEN'S BLEEDING DISORDERS COMMUNITY	Debra Pollard
ABS289	CINDERELLA: WOMEN'S LIVED EXPERIENCES OF BLEEDING DISORDERS	Debra Pollard
ABS290	EMI AND ME: AN INTERIM REPORT	Simon Fletcher
ABS291	EUROPEAN PRINCIPLES OF CARE FOR WOMEN AND GIRLS WITH INHERITED BLEEDING DISORDERS	Karin van Galen
ABS292	EXIGENCY: UK HEALTHCARE PROFESSIONALS’ EXPERIENCE SUPPORTING PEOPLE WITH HAEMOPHILIA UNDERGOING GENE THERAPY	Debra Pollard
ABS293	EXIGENCY: WHY SOME PEOPLE WITH HAEMOPHILIA HAVE NO INTEREST IN GENE THERAPY	Simon Fletcher
ABS294	IMPACT OF LOCKDOWN ON SERVICE CAPABILITY OF UK HAEMOPHILIA CENTRES	Nicola Sugg
ABS295	MOOD BEFORE AND AFTER THE PERFORMANCE OF A RECREATIONAL-SPORTS ACTIVITY FOR PATIENTS WITH COAGULOPATHIES AND CARRIERS PARTICIPATING IN A WELLNESS PROGRAM.	Elena González-Zorrilla